Hader T, Molderings G, Klawonn F, Conrad R, Mucke M, Sellin J
Dig Dis Sci. 2023; 68(8):3400-3412.
PMID: 37029308
PMC: 10352424.
DOI: 10.1007/s10620-023-07921-5.
Bossi G, Brazzelli V, De Amici M, Pietra D, Raviola C, Naso M
Ital J Pediatr. 2023; 49(1):6.
PMID: 36639823
PMC: 9839392.
DOI: 10.1186/s13052-022-01402-7.
Gulen T, Akin C
Curr Allergy Asthma Rep. 2021; 21(2):11.
PMID: 33560495
PMC: 7873102.
DOI: 10.1007/s11882-021-00988-y.
Yalcin A, Onbasi K, Uzun R, Herth F, Schnabel P
Cent Eur J Immunol. 2021; 45(2):195-201.
PMID: 33456331
PMC: 7792442.
DOI: 10.5114/ceji.2020.97909.
Le M, Gabrielli S, De Schryver S, Ben-Shoshan M
Open Access Emerg Med. 2019; 11:249-263.
PMID: 31802955
PMC: 6830385.
DOI: 10.2147/OAEM.S200342.
Efficacy of Omalizumab in Indolent Systemic Mastocytosis.
Slapnicar C, Trinkaus M, Hicks L, Vadas P
Case Rep Hematol. 2019; 2019:3787586.
PMID: 31637065
PMC: 6766258.
DOI: 10.1155/2019/3787586.
Bone Marrow Mast Cell Antibody-Targetable Cell Surface Protein Expression Profiles in Systemic Mastocytosis.
Dasilva-Freire N, Mayado A, Teodosio C, Jara-Acevedo M, Alvarez-Twose I, Matito A
Int J Mol Sci. 2019; 20(3).
PMID: 30696068
PMC: 6387409.
DOI: 10.3390/ijms20030552.
Cutaneous mastocytosis treatment: strategies, limitations and perspectives.
Czarny J, Lange M, Lugowska-Umer H, Nowicki R
Postepy Dermatol Alergol. 2019; 35(6):541-545.
PMID: 30618520
PMC: 6320483.
DOI: 10.5114/ada.2018.77605.
Mast cell disorders: Protean manifestations and treatment responses.
Chen M, Kim A, Zuraw B, Doherty T, Christiansen S
Ann Allergy Asthma Immunol. 2018; 121(1):128-130.
PMID: 29604336
PMC: 6026564.
DOI: 10.1016/j.anai.2018.03.027.
Targeted Treatment Options in Mastocytosis.
Vaes M, Benghiat F, Hermine O
Front Med (Lausanne). 2017; 4:110.
PMID: 28775983
PMC: 5517467.
DOI: 10.3389/fmed.2017.00110.
IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navines-Ferrer A, Serrano-Candelas E, Molina-Molina G, Martin M
J Immunol Res. 2017; 2016:8163803.
PMID: 28097159
PMC: 5209625.
DOI: 10.1155/2016/8163803.
Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.
Gonzalez-de-Olano D, Matito A, Orfao A, Escribano L
F1000Res. 2016; 5:2666.
PMID: 27909577
PMC: 5112577.
DOI: 10.12688/f1000research.9565.1.
Pharmacological treatment options for mast cell activation disease.
Molderings G, Haenisch B, Brettner S, Homann J, Menzen M, Dumoulin F
Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(7):671-94.
PMID: 27132234
PMC: 4903110.
DOI: 10.1007/s00210-016-1247-1.
Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy.
Vestergaard C, Deleuran M
Ther Adv Chronic Dis. 2015; 6(6):304-13.
PMID: 26568807
PMC: 4622315.
DOI: 10.1177/2040622315603951.
Advances in anti-IgE therapy.
Yalcin A
Biomed Res Int. 2015; 2015:317465.
PMID: 26075226
PMC: 4436440.
DOI: 10.1155/2015/317465.
Off-Label Uses of Omalizumab.
El-Qutob D
Clin Rev Allergy Immunol. 2015; 50(1):84-96.
PMID: 26048266
DOI: 10.1007/s12016-015-8490-y.
Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.
Lieberoth S, Thomsen S
Case Rep Med. 2015; 2015:903541.
PMID: 25694784
PMC: 4324745.
DOI: 10.1155/2015/903541.
An overview of the effects of anti-IgE therapies.
Yalcin A
Med Sci Monit. 2014; 20:1691-9.
PMID: 25241913
PMC: 4181307.
DOI: 10.12659/MSM.890137.
